Your session is about to expire
← Back to Search
IXT-m200 for Methamphetamine Intoxication (Meth-OD Trial)
Meth-OD Trial Summary
This trial is testing a new antibody to see if it's effective and safe in treating people with mild to moderate methamphetamine toxicity.
- Methamphetamine Intoxication
Meth-OD Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 1 & 2 trial • 77 Patients • NCT03336866Meth-OD Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
To what extent does IXT-m200 pose a threat to human health?
"Taking all information into consideration, our team at Power assigned IXT-m200 a safety score of 2 as it is only in Phase 2 clinical trials. This suggests some evidence of its safety but no proof yet of efficacy."
What other research has been undertaken featuring IXT-m200?
"Initially studied in 2012 at Chaim Sheba Medical Center, IXT-m200 has since been subject to 143 completed investigations. Currently, 15 trials are running around the world; with a concentration of them being located in Spokane, Washington."
How many individuals are being included in this research program?
"This clinical trial necessitates 40 participants, meeting the established criteria, to participate. Those interested can enrol at Sacred Heart Medical Center in Spokane or Providence Regional Medical Center Everett in New mexico."
Are there any restrictions on who may participate in this clinical experiment?
"This clinical experiment is accepting individuals aged between 18 and 45 who have experienced a drug overdose. Currently, 40 participants are required to complete the trial."
Is this research project still accepting participants?
"This clinical trial, which was inaugurated on June 30th 2021, is still actively seeking participants. The study's specifications were last amended on December 7th 2022 according to data available from clinicialtrials.gov."
For what applications is IXT-m200 typically employed?
"IXT-m200 is an investigational drug that has potential in treating schizophrenia, phencyclidine intoxication, and terminal illness palliative care."
Is the patient pool for this trial restricted to those under 40 years of age?
"As stated in the prerequisites for participation, individuals must be between 18 and 45 years old to qualify."
What is the main goal of this investigation?
"This 28-day trial intends to measure the amount of treatment related adverse events through laboratory tests. Secondary targets include tracking changes in blood pressure and heart rate over time, as well as recording patients who need additional medication for psychiatric or cardiovascular reactions to methamphetamine toxicity."
Are there numerous medical facilities in North America that are currently conducting the clinical investigation?
"At the current moment, 4 medical centres are participating in this trial. These locations can be found in Spokane Washington, Everett Washington, Albuquerque New mexico and at additional facilities. If you plan to join this study it is crucial that you select a site nearest your abode to reduce commuting requirements."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger